Related Experiment Videos
Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow
L A Ochs1, W J Miller, A H Filipovich
1Department of Medicine, University of Minnesota, Minneapolis.
Insights
Previous acute graft-versus-host disease (GVHD) significantly increases chronic GVHD risk after bone marrow transplantation (BMT). Patient age and donor-recipient sex match also impact chronic GVHD development, informing clinical trial design.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Allogeneic bone marrow transplantation (BMT) is a critical treatment for various hematologic malignancies.
- Graft-versus-host disease (GVHD) remains a significant complication following allogeneic BMT.
- Understanding risk factors for chronic GVHD is crucial for improving patient outcomes.
Purpose of the Study:
- To identify and analyze independent risk factors associated with the development of chronic graft-versus-host disease (GVHD) after matched sibling allogeneic bone marrow transplantation (BMT).
- To stratify patients into distinct risk groups based on identified predictive factors for chronic GVHD.
Main Methods:
- Retrospective analysis of 469 consecutive patients undergoing matched sibling allogeneic BMT.
- Multivariate analysis to determine independent risk factors for chronic GVHD.
- Risk stratification based on previous acute GVHD severity and recipient age.
Main Results:
- The overall incidence of chronic GVHD was 41 +/- 6% between 2 and 50 months post-BMT.
- Previous acute GVHD was the dominant independent risk factor (Relative Risk 4.82, p < 0.0001).
- Recipient age (>= 18 years) and male recipient with female donor were also significant independent predictors.
Conclusions:
- Previous acute GVHD, recipient age, and donor-recipient sex match are key independent predictors of chronic GVHD post-BMT.
- Patients with advanced acute GVHD face the highest risk (70 +/- 8%) of developing chronic GVHD.
- These factors are essential for designing and evaluating clinical trials for chronic GVHD prophylaxis and treatment.
Abstract:
We analyzed factors associated with the development of chronic graft-versus-host disease (GVHD) in 469 consecutive patients receiving matched sibling allogeneic bone marrow transplantation (BMT). Overall, 41 +/- 6% (95% confidence interval) developed chronic GVHD between 2 and 50 months after BMT. Multivariate analysis showed that previous acute GVHD was the dominant independent risk factor predisposing to chronic GVHD (Relative Risk 4.82, p < 0.0001). In addition, recipient age of > or = 18 years and male recipient with female donor were also independent predictive factors for development of chronic GVHD. When acute GVHD and recipient age were considered, groups with distinctive risks of chronic GVHD were identified. Patients under 18 without previous grade II-IV acute GVHD had only a 10 +/- 5% risk of chronic GVHD. Patients over 18 with no prior grade II-IV acute GVHD had a 31 +/- 12% risk while patients with advanced acute GVHD, regardless of age, had the highest risk and 70 +/- 8% developed chronic GVHD. It is important to consider these factors when designing and assessing clinical trials of chronic GVHD prophylaxis and treatment.